



RELiZORB®

(iMMOBILIZED LIPASE) CARTRIDGE

Redesigned RELiZORB: Frequently Asked Questions

RELiZORB is indicated for use in pediatric patients (ages 2 years and above) and adult patients to hydrolyze fats in enteral formula.

Why is RELiZORB changing?

Not every enterally-fed patient has the same approach to feeding. In order to better support the needs of tube-fed patients, RELiZORB has been redesigned for expanded utilization.

How can I tell which RELiZORB is new?

RELiZORB has a new look on both the packaging and the product—look for the orange cap on the new RELiZORB.

Can RELiZORB be used the same way as before?

Yes, RELiZORB connects directly to your patient's feeding tube and is still ENFit compatible. RELiZORB will have expanded utilization, including:

- compatibility with continuous & bolus feeding
- an increase to use up to 6 cartridges per day
- expanded formula compatibility, allowing for use with some formulas with insoluble fibers

See full Instructions for Use at relizorbhcp.com.

Can RELiZORB be used with the same formulas?

Yes, and in addition, RELiZORB is now compatible with a greater range of formulas, including some with insoluble fiber. To see a list of RELiZORB compatible formulas and pumps, visit relizorbhcp.com.

Are there changes to how RELiZORB is reimbursed?

There are no changes to billing, coding, or patient enrollments.

RELiZORB is for use with enteral feeding only; do not connect to intravenous or other medical tubing. Medications should not be administered through RELiZORB.

Please see Instructions for Use at relizorbhcp.com

Will RELiZORB still contain iLipase®?

RELiZORB still contains iLipase®, the digestive enzyme lipase attached to small microbead carriers, which breaks down fats in enteral formulas as they pass through the cartridge, delivering absorbable fats to your patient's body. The iLipase remains in the cartridge and is not ingested.

Is the new RELiZORB safe and effective?

Yes, there are no changes to the safety or efficacy of RELiZORB. RELiZORB is still the only FDA-cleared enzyme product to break down fats in enteral formula.

When will my patients receive the new RELiZORB?

You and your patients should expect to see the updated RELiZORB in the coming months. You and your patients should continue to feel confident using existing RELiZORB product.

Where can I learn more about the new product rollout?

Learn more by contacting your RELiZORB Account Manager or scan the QR code below.

Do current RELiZORB patients need to be re-enrolled in RELiZORB Support Services?

No, current patients who are already receiving RELiZORB and are enrolled in RELiZORB Support Services will not need to be re-enrolled.



Scan now to learn about the redesigned RELiZORB

RELiZORB®

(IMMOBILIZED LIPASE) CARTRIDGE



[RELiZORBhcp.com](https://www.RELiZORBhcp.com)



Scan now to learn more about
the redesigned RELiZORB



ENFit® is a registered trademark of GEDSA.
RELiZORB, iLipase, the Alcresta capstone, and Alcresta Therapeutics
are registered trademarks of Alcresta Therapeutics, Inc.
Patents: <http://www.alcresta.com/patents>
©2024 Alcresta Therapeutics, Inc. All rights reserved. REL2023-1486